14/02/2019 13:15:00

Fortune Magazine names Stryker one of the 100 Best Companies to Work For in 9th consecutive year

Kalamazoo, Michigan, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Kalamazoo, Michigan – February 14, 2019 – Stryker (NYSE:SYK) announced today it has been named one of Fortune’s 2019 100 Best Companies to Work For in its annual survey and evaluation of top-rated workplaces in the United States. The list recognizes companies that have exceptional workplace cultures. This is the ninth consecutive year Stryker has been named to the list, and the company was ranked #11. The full list and related stories are available at https://fortune.com/best-companies/list.

“We are one of the 100 Best Companies to Work For because of our people,” said Katy Fink, Vice President, Chief Human Resources Officer, Stryker. “Our talented employees live our mission and values every day and go above and beyond to make healthcare and our workplace better. We thank them for their passion, commitment and drive to make Stryker a special place to work.” 

Fortune partners with research firm Great Place to Work (GPTW) to create the list. GPTW scores each company on its analysis of anonymous employee responses to more than 60 questions on the Trust Index Survey. The survey represents the feedback of more than 4.3 million employees across the U.S. In addition, GPTW evaluated each companies’ programs and practices as measured through its Culture Audit© assessment.

GPTW ranks the 100 Best Companies to Work For by comparing participants’ scores against similarly sized peers to choose companies that perform the best on characteristics such as being a great place to work for all, executive team effectiveness, innovation and people-focused programs. GPTW research shows that list winners keep outperforming the stock market, beating industry rivals when it comes to talent retention and demonstrating higher levels of productivity than peers.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:

Katherine A. Owen, Vice President, Strategy & Investor Relations at 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact:

Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
21 Jul
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
16
17 Jul
I:SP500
På verdensplan vil næsten ingen acceptere økonomisk tilbageholdenhed til fordel for klimaet. En mill..
16
18 Jul
 
Foranlediget lidt af debatten i den sidste uges tid, kommer her fredagsjoken: En investor her på EI..
15
20 Jul
TEVA
Henningmaria: Casen omkring Teva har ikke ændret sig fundamentalt blot folks følelser pga verserende..
13
17 Jul
I:SP500
Tøjindustrien står for 10 % af udslippet af klimagasser ifølge The Angry Clean Energy Guy. Det er me..
13
17 Jul
 
Jeg er kvinde på 75 år og har haft afdragsfrit lån i 10 år. Min tidligere bankrådgiver, som vdste mi..
12
16 Jul
VELO
At der er nogle som hiver lidt gevinst hjem. Fred være med det. Velo skal op i en helt anden kurs, n..
12
15 Jul
BAVA
Tænk engang, med alt det du skriver om Bavarian og ebola vaccinen, så skulle man tro, at du bare ved..
12
18 Jul
VELO
Jeg havde ligeledes håbet der var mulighed for at supplere lidt længere nede, men nu hedder det nok ..
11
15 Jul
VELO
At optimisme er et advarselstegn er da hul i hovedet. Det kommer an på hvad optimismen bunder i. For..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Two Decades Of Value Delivery And Partnership In Mali
2
TM enters into exclusive negotiations with Klakki ehf. on the purchase of Lykill fjármögnun hf.
3
Oncology Venture – First day of trading in investor warrants
4
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
5
PRICESMART 24 HOUR DEADLINE ALERT: APPROXIMATELY 24 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against PriceSmart, Inc. - PSMT

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 July 2019 07:21:32
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB4 - 2019-07-22 08:21:32 - 2019-07-22 07:21:32 - 1000 - Website: OKAY